I-Mab Advances Givastomig in Gastric Cancer with Promising Clinical Data

I-Mab (NASDAQ: IMAB), a U.S.-based biotech company specializing in immuno-oncology, has announced its participation in the H.C. Wainwright virtual "HCW@Home" Series on June 17, 2025. The company's management team will engage in a fireside chat focused on Claudin 18.2 as a therapeutic target for gastric cancers, with particular emphasis on their drug candidate givastomig, a Claudin 18.2 x 4-1BB bispecific antibody. The discussion will feature CEO Sean Fu and CMO Phillip Dennis, moderated by H.C. Wainwright Senior Analyst Andres Maldonado. Notably, givastomig's Phase 1 dose escalation study results in combination with immunochemotherapy have been selected for presentation at the upcoming ESMO GI Cancers Congress on July 2, 2025.

https://www.stocktitan.net/news/IMAB/i-mab-to-participate-in-the-h-c-wainwright-hcw-home-sik96hffq4nj.html